|
WO2009015279A2
|
|
Agents and methods for inhibition of airway hyperresponsiveness
|
|
US2008248025A1
|
|
Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions
|
|
WO2008101084A2
|
|
Methods and compositions for the disruption of biofilms
|
|
WO2008014420A2
|
|
Non-human animal models for b-cell non-hodgkin's lymphoma and uses thereof
|
|
WO2007041610A2
|
|
Genes and proteins associated with angiogenesis and uses thereof
|
|
WO2007024741A2
|
|
Methods for treatment of thiol-containing compound deficient conditions
|
|
WO2007009128A2
|
|
Methods and compositions for 10beryllium complex probes
|
|
US2006223769A1
|
|
Methods of using nucleic acid vector-lipid complexes
|
|
US2006094054A1
|
|
Fibulin-3 and uses thereof
|
|
EP1791566A2
|
|
Product and process for inhibition of biofilm development
|
|
WO2005094269A2
|
|
Mucolytic and anti-elastase compounds and methods of use thereof
|
|
AU2005200731A1
|
|
Method for reducing allergen-induced airway hyperresponsiveness
|
|
EP1613731A2
|
|
Modified adenoviral e1a constructs and methods of use thereof
|
|
WO2004078948A2
|
|
METHOD TO IDENTIFY REGULATORS OF CELLULAR ACTIVATION USING Bcl10
|
|
AU2003287398A1
|
|
Methods for treatment of thiol-containing compound deficient conditions
|
|
EP1551455A2
|
|
Product and process for liquefaction of mucus or sputum
|
|
AU2003268089A8
|
|
Method for identifying mhc-presented peptide epitopes for t cells
|
|
AU2003222043A1
|
|
Method for production of neutrophils and uses therefor
|
|
US2003202962A1
|
|
Gene therapy for effector cell regulation
|
|
WO03060097A2
|
|
USE OF SOLUBLE Ϝδ T CELL RECEPTORS FOR REGULATING T CELL FUNCTION
|
